News

/News/

What is the reality of the introduction of international reference pricing for Medicare drug prices in the US?

High US pharmaceutical drug prices have been a major discussion topic for several years now, but recent proposals by the US administration to use drug prices in other countries to help Medicare negotiate with drug companies appear to be radical. What are the proposals and what do they mean for pharmaceutical manufacturers?

Medicare and the International Pricing Index Model

Put very simply, Medicare would use a new International Pricing Index (IPI) model that considers international reference prices to negotiate drug prices with manufacturers.

Under the current proposals, the Centres for Medicare and Medicaid Services (CMS) would be able to undertake a five-year experiment with Medicare drug prices. The experiment would only consider Medicare Part B drugs, which account for ~29% of US prescription drug spending, excluding Medicare Part D drugs.

In the proposed experiment, the US would be split into two geographical regions, with 50% negotiating Part B prices using existing methods, […]

By |2018-12-12T10:23:49+00:00December 12th, 2018|News|0 Comments

How NICE’s META tool can assist with UK patient access for your MedTech product?

Remap Consulting have recently been accredited by NICE as a META tool facilitating organisation that can support MedTech manufacturers in understanding what evidence is needed to make a convincing case to UK payers to demonstrate the value of their technology to patients and the healthcare system.

What is the META tool?

NICE has recently developed the META (MedTech Early Technical Assessment) tool, to support MedTech manufacturers in the identification of potential evidence gaps, that can hinder a NICE assessment. The outputs of the META tool will help you be able to develop an understanding of the evidence needed to demonstrate your product’s value to the NHS and identify evidence gaps that may delay patient access for your product.

The META tool has been designed to help developers of both large and small, of medical technologies that have, or are expected to obtain, a CE mark. The tool is designed to […]

By |2018-12-03T13:21:51+00:00December 3rd, 2018|News|0 Comments

Market Access Training Workshops

Are you involved in discussions around market access, but have never received any formal market access training? Do you worry that your market access knowledge may be out-of-date in a complex and rapidly evolving field? If so, our introductory workshops to pricing and market access may be just the thing you need. Held in Zurich on 27th and 28th March 2019, places are available on either (or both) days, depending on your training needs. Find out more by clicking the link below:

Market Access Training Workshops

By |2018-11-29T09:02:44+00:00November 29th, 2018|News|0 Comments

Pfizer to hike list price of 41 medicines

Article written by: Joe Barber

Pfizer has announced that it plans to increase the list price of 41 medicines, or 10 percent of its entire drug portfolio, as of January 15. The company indicated that “the increase in list price to this subset of [our] portfolio will be 5 percent,” with the only exceptions being three drugs, which will see their prices rise 3 percent, and one other product, whose cost will jump 9 percent. List prices for the remainder of the portfolio will be unchanged, the drugmaker said.

Read full article here: https://goo.gl/uZ7A5d

 

 

By |2018-11-19T11:11:12+00:00November 19th, 2018|News|0 Comments

Remap team presenting their research at ISPOR Barcelona

The team at Remapconsulting are proud to be presenting 3 of their posters today and are looking forward to discussing their research

K30: DO COMPANIES’ MARKET ACCESS TRAINING CAPABILITIES ADDRESS THE NEEDS OF TODAY’S COMPLEX PAYER MARKETPLACE? https://goo.gl/RRbWtD

N34: WHAT ARE THE KEY CONSIDERATIONS FOR SEEKING PAYER SCIENTIFIC ADVICE IN THE EU? https://goo.gl/6Sv6Sm

O13: EXPLORING BIOSIMILAR MARKET ACCESS CONSIDERATIONS ACROSS EUROPE https://goo.gl/SQsYWx

By |2018-11-13T08:56:57+00:00November 13th, 2018|News|0 Comments

Remap are to present 5 research posters at ISPOR 2018

The team at Remap Consulting will be presenting 5 research posters at the #ISPOR congress in Barcelona next week.

Come along and meet the team at booth 901, discuss our findings or have a chat about your pricing and market access challenges.

Looking forward to seeing you there.

 

By |2018-11-06T15:14:20+00:00November 6th, 2018|News|0 Comments